Becton, Dickinson and Company (BDX) Q3 FY25 earnings call

The company delivered strong Q3 FY25 results, exceeding margin and EPS expectations, driven by commercial initiatives and BD Excellence. Progress was made on the Biosciences and Diagnostic Solutions separation, expected to close in Q1 CY26. Management reaffirmed organic revenue guidance while raising EPS, despite persistent market headwinds and tariff impacts, by reinvesting in growth opportunities.